Stroke and bleeding with non-Vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: A population-based cohort study

Europace

Volumn 20, Issue 3, 2018, Pages 420-428

  Forslund, Tomas ^a   Wettermark, Björn ^a   Andersen, Morten ^a   Hjemdahl, Paul ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anticoagulant treatment; Atrial fibrillation; Bleeding; NOAC; Stroke; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN;

AGED; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHA2DS2-VASC SCORE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TRANSIENT ISCHEMIC ATTACK; VERY ELDERLY; CHEMICALLY INDUCED; ORAL DRUG ADMINISTRATION; REGISTER; RISK FACTOR; SWEDEN; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; REGISTRIES; RISK FACTORS; STROKE; SWEDEN; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 85041047419     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euw416     Document Type: Article

References (16)

1. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-413.
2. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016;18:1609-78.
3. Forslund T, Wettermark B, Wandell P, von Euler M, Hasselström J, Hjemdahl P. Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region. Eur J Clin Pharmacol 2014;70:1477-85.
4. Forslund T, Wettermark B, Wandell P, von Euler M, Hasselstrom J, Hjemdahl P. Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: experience from the Stockholm health care system. lnt J Cardiol 2013;170:208-14.
5. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. (for the RE-LY Investigators). Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
6. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. (for the ROCKET AF Investigators). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
7. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al. (for the ARISTOTLE Investigators). Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
8. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975-83.
9. Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S et al. for the ARISTOTLE Investigators. Efficacy and safety of apixaban compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation. Circulation 2013;127:2166-76.
10. Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc 2013;2: doi: 10.1161/JAHA.112.000067.
11. Björck F, Renlund H, Lip GYH, Wester P, Svensson PJ, Sjalander A. Outcomes in a warfarin-treated population with atrial fibrillation. JAMA Cardiol 2016;1:172-180.
12. Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2016;353:i3189.
13. Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc 2016;5:e003725.
14. Friberg L, Skeppholm M, Terént A. Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. J Am Coll Cardiol 2015;65:225-32.
15. Friberg L, Skeppholm M. Usefulness of health registers for detection of bleeding events in outcome studies. Thromb Haemost 2016;116:1131-1139.
16. Hosmer DW, Lemeshow S, May S. Applied Survival Analysis: Regression Modeling of Time-To-Event Data. 2nd ed. Hoboken, NJ: John Wiley & Sons, Inc; 2008.